Is Editas Medicine Facing A New Reality In CRISPR Land?

Published: May 17, 2017

Editas Medicine Inc. (NASDAQ: EDIT) is one of the biotech and biohealth players that sits on the cusp of new technology and developments for the next major growth phase in health care: CRISPR. Big opportunities in emerging health care companies often come with very bumpy rides. There is also the risk, of course, that there are no assurances that the potential promise and upside will come true in the future. Editas shares were lower after its earnings report, but the main culprit is a delay to the company’s Leber congenital amaurosis (LCA) treatment. This is a rare, degenerative disease in the retina that causes blindness in children.

Back to news